Aura Paris
- Address
- 12 Rue Anselme, 93400 Saint-Ouen-sur-Seine, France
Genetic Kidney Disease Research
At Aura Paris, clinical research in Genetic Phenomena focuses on inherited kidney disorders, especially APOL1 Kidney Disease and APOL1-mediated Proteinuric Kidney Disease. These studies are designed to assess new treatment options and better understand how targeted therapies may help protect kidney function.
- Evaluating the safety and effectiveness of a new therapy for APOL1-mediated Proteinuric Kidney Disease
- Studying treatment approaches for adults and children affected by APOL1 Kidney Disease
- Testing whether targeted care can improve outcomes in proteinuric kidney disease
These trials reflect a strong interest in precision medicine for kidney conditions linked to genetic risk, with a focus on improving long-term renal health.
Cardiovascular and Kidney Complications
Research in Cardiovascular Diseases at this site examines serious heart-related risks in people with advanced kidney disease, including atherosclerotic cardiovascular disease and atrial fibrillation in the setting of Chronic Kidney Disease stage 5. The studies aim to improve stroke prevention and reduce cardiovascular complications in patients receiving dialysis or living with severe renal impairment.
- Assessing whether a blood-thinning treatment can lower stroke risk in people with atrial fibrillation and advanced kidney disease
- Exploring ways to reduce atherosclerotic cardiovascular disease in patients with end-stage kidney disease
- Evaluating treatment safety in people with CKD stage 5 who may also be on dialysis
The Dialyse department is contributing to research that connects kidney failure with major cardiovascular outcomes, an important area for patient safety and quality of care.
Musculoskeletal and Inflammatory Conditions
Clinical trials in Musculoskeletal Diseases are addressing painful inflammatory conditions, particularly gout attacks in people with advanced kidney disease, including those on dialysis or after kidney transplantation. The goal is to compare treatment options and improve symptom control in patients who have limited medication choices because of reduced kidney function.
- Comparing therapies for gout flare treatment in patients with chronic kidney disease
- Studying better ways to manage inflammation during acute gout attacks
- Evaluating treatment effectiveness in people with kidney failure and painful joint disease
By focusing on inflammation-related pain in complex kidney patients, this research aims to support safer and more effective care.
Dialysis-Related Inflammation and Kidney Failure Studies
Several trials at Aura Paris involve people with end-stage kidney disease undergoing maintenance dialysis. These studies look at inflammatory markers and broader treatment outcomes, with the aim of improving health management in patients living with advanced renal failure.
- Testing whether treatment can lower inflammation in dialysis patients
- Evaluating the impact of new therapy on cardiovascular risk in ESKD
- Studying treatment options for adults with severe kidney disease receiving dialysis
This area of research is especially relevant for patients with long-term renal failure, where controlling inflammation and related complications may improve overall outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1CSL Behring LLC1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aura Paris
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anakinra | 1 | Unknown | 2022-06-02 | 2022-06-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.